157 related articles for article (PubMed ID: 28506734)
21. Evaluation of the relationship between c-Kit expression and mean platelet volume in classic Kaposi's sarcoma.
Sehitoglu I; Bedir R; Cure E; Cure MC; Yuce S; Dilek N
An Bras Dermatol; 2016; 91(4):430-5. PubMed ID: 27579736
[TBL] [Abstract][Full Text] [Related]
22. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
23. Akt pathway protein expression in gastrointestinal Kaposi sarcomas: relevance for tumor biology.
Badescu A; Couvelard A; Handra-Luca A
APMIS; 2014 Jun; 122(6):518-25. PubMed ID: 24286304
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
Krown SE; Roy D; Lee JY; Dezube BJ; Reid EG; Venkataramanan R; Han K; Cesarman E; Dittmer DP
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):447-54. PubMed ID: 22067664
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of endothelial markers and HHV-8 staining in gastrointestinal Kaposi sarcoma and its difference in endoscopic tumor staging.
Nagata N; Igari T; Shimbo T; Sekine K; Akiyama J; Hamada Y; Yazaki H; Ohmagari N; Teruya K; Oka S; Uemura N
World J Gastroenterol; 2013 Jun; 19(23):3608-14. PubMed ID: 23801862
[TBL] [Abstract][Full Text] [Related]
26. Variability of HHV8 LNA-1 Immunohistochemical Staining Across the 3 Histologic Stages of HIV-Associated Mucocutaneous Kaposi Sarcoma: Is There a Relationship to Patients' CD4 Counts?
Mohanlal RD; Pather S
Am J Dermatopathol; 2015 Jul; 37(7):530-4. PubMed ID: 26091511
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic Correlation of Kaposi Sarcoma Involving the Ocular Adnexa: Immunophenotyping of Diagnostic and Therapeutic Targets.
Ulloa-Padilla JP; Ghassibi MP; Dubovy SR; Kerr DA
Ophthalmic Plast Reconstr Surg; 2020; 36(2):185-190. PubMed ID: 31743287
[TBL] [Abstract][Full Text] [Related]
28. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
29. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.
Roy D; Sin SH; Lucas A; Venkataramanan R; Wang L; Eason A; Chavakula V; Hilton IB; Tamburro KM; Damania B; Dittmer DP
Cancer Res; 2013 Apr; 73(7):2235-46. PubMed ID: 23382046
[TBL] [Abstract][Full Text] [Related]
30. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
[TBL] [Abstract][Full Text] [Related]
31. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.
Daly ML; Fogo A; McDonald C; Morris-Jones R
Clin Exp Dermatol; 2014 Jan; 39(1):7-12. PubMed ID: 23691969
[TBL] [Abstract][Full Text] [Related]
32. Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma.
Montaner S
Cell Cycle; 2007 Feb; 6(4):438-43. PubMed ID: 17329974
[TBL] [Abstract][Full Text] [Related]
33. Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.
Chen H; Guan R; Lei Y; Chen J; Ge Q; Zhang X; Dou R; Chen H; Liu H; Qi X; Zhou X; Chen C
BMC Cancer; 2015 Mar; 15():103. PubMed ID: 25884175
[TBL] [Abstract][Full Text] [Related]
34. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
35. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
36. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
[TBL] [Abstract][Full Text] [Related]
37. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science.
Dezube BJ; Sullivan R; Koon HB
J Cell Physiol; 2006 Dec; 209(3):659-62. PubMed ID: 17001705
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
Potti A; Ganti AK; Kargas S; Koch M
Anticancer Res; 2002; 22(5):2899-901. PubMed ID: 12530014
[TBL] [Abstract][Full Text] [Related]
39. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
